Results
21,591 records
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 37 | Fang AndyDirector |  DASHDoorDash, Inc.Open-market sale · 10b5-1 plan | SELL | $789K 3,796 sh | Feb 4, 2026 |
Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramEvery ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 37 | Fang AndyDirector | DASHDoorDash, Inc. Open-market sale · 10b5-1 plan | SELL | $789K 3,796 sh | Feb 4, 2026 |
| 37 | Fang AndyDirector | DASHDoorDash, Inc. Open-market sale · 10b5-1 plan | SELL | $304K 1,446 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 36 | Anderson Barbara J.Director |  TFSLTFS Financial CORPOpen-market sale | SELL | $156K 11.0K sh | Feb 4, 2026 traded Feb 3, 2026 |
| 34 | Procacci RiccardoSenior Vice President |  GEGENERAL ELECTRIC COOpen-market sale | SELL | $248K 800 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 31 | Kim Peter Sung-JipSVP & GM Industrial Business |  LFUSLITTELFUSE INC /DEOpen-market sale | SELL | $27K 82 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 29 | Bernstein HaroldPresident, R&D & CMO |  MAZEMaze Therapeutics, Inc.Open-market sale · 10b5-1 plan | SELL | $275K 5,936 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 29 | Bernstein HaroldPresident, R&D & CMO | MAZEMaze Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $384K 8,364 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 28 | Monroe CarolynSVP - Title Insurance |  ORIOLD REPUBLIC INTERNATIONAL CORPOpen-market sale | SELL | $63K 1,600 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 28 | Monroe CarolynSVP - Title Insurance | ORIOLD REPUBLIC INTERNATIONAL CORP Open-market sale | SELL | $154K 3,926 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 26 | Tang StanleyDirector | DASHDoorDash, Inc. Open-market sale · 10b5-1 plan | SELL | $114K 560 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 26 | Tang StanleyDirector | DASHDoorDash, Inc. Open-market sale · 10b5-1 plan | SELL | $207K 1,000 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 25 | Moore Alexander D.Director |  PLTRPalantir Technologies Inc.Open-market sale · 10b5-1 plan | SELL | $1.38M 9,212 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 25 | Novack Jeffrey AdamSecretary and General Counsel |  CDNACareDx, Inc.Open-market sale | SELL | $91K 4,441 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 23 | Bernstein HaroldPresident, R&D & CMO | MAZEMaze Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $4,723 100 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 23 | Stat Lauren Elaina FriedmanDirector | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $60K 400 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 23 | Fang AndyDirector | DASHDoorDash, Inc. Open-market sale · 10b5-1 plan | SELL | $16K 80 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 23 | Fang AndyDirector | DASHDoorDash, Inc. Open-market sale · 10b5-1 plan | SELL | $41K 200 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 23 | Fang AndyDirector | DASHDoorDash, Inc. Open-market sale · 10b5-1 plan | SELL | $8,162 40 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 22 | Rabinowitz DanielSEC. AND CHIEF LEGAL OFFICER |  NTRANatera, Inc.Open-market sale · 10b5-1 plan | SELL | $308K 1,334 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 22 | Smith Michael AlexanderChief Legal Officer |  INSMINSMED IncOpen-market sale | SELL | $100K 640 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 22 | Fesko JohnPRESIDENT, CHIEF BUS. OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $558K 2,415 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 22 | Moore Alexander D.Director | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $374K 2,525 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 22 | Fesko JohnPRESIDENT, CHIEF BUS. OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $272K 1,179 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 22 | Moore Alexander D.Director | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $942K 6,310 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 21 | Mat IshbiaDirector, President and CEO, 10% Owner |  UWMCUWM Holdings CorpOpen-market sale · 10b5-1 plan | SELL | $3.30M 632.9K sh | Feb 4, 2026 traded Feb 3, 2026 |
| 21 | Mat IshbiaDirector, President and CEO, 10% Owner | UWMCUWM Holdings Corp Open-market sale · 10b5-1 plan | SELL | $3.20M 632.9K sh | Feb 4, 2026 traded Feb 4, 2026 |
| 20 | Schwartz Richard ToddDirector, Chief Executive Officer |  RSIRush Street Interactive, Inc.Open-market sale · 10b5-1 plan | SELL | $4.35M 247.1K sh | Feb 4, 2026 traded Feb 4, 2026 |
| 20 | Malenka Robert C.Director |  MPLTMapLight Therapeutics, Inc.Open-market sale | SELL | $127K 7,039 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Bachrodt AmySVP, Finance | MAZEMaze Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $187K 4,064 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Moore Alexander D.Director | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $186K 1,233 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $378K 1,639 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 19 | Moore Alexander D.Director | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $106K 720 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 18 | Howse CurtisSee remarks |  SYFSynchrony FinancialOpen-market sale · 10b5-1 plan | SELL | $3.80M 52.6K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Malabre Richard CSVP, Chief Accounting Officer |  AKBAAkebia Therapeutics, Inc.Open-market sale · 10b5-1 plan | SELL | $50K 36.1K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Malenka Robert C.Director | MPLTMapLight Therapeutics, Inc. Open-market sale | SELL | $18 1 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $140K 600 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Stetz MattiasChief Operating Officer | RSIRush Street Interactive, Inc. Open-market sale · 10b5-1 plan | SELL | $353K 20.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $202K 878 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $197K 850 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $133K 576 sh | Feb 4, 2026 traded Feb 2, 2026 |